VIBRIO CHOLERAE TCP AND LPS SUBUNIT VACCINE, EPITOPES AN

霍乱弧菌 TCP 和 LPS 亚单位疫苗，表位 AN

• 批准号: 6091773
• 负责人: WILLIAM Franklin WADE
• 金额: $ 31.8万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6091773
• 关键词: B lymphocyte; T lymphocyte; Vibrio cholerae; bacterial antigens; cholera toxin; cholera vaccine; enzyme linked immunosorbent assay; epitope mapping; gene therapy; humoral immunity; laboratory mouse; lipopolysaccharides; vaccine development; vector vaccine

Cholera is an acute diarrheal disease caused by the gram-negative bacterium, Vibrio cholerae. Following ingestion of contaminated food or water, bacteria colonize the small intestine and secrete cholera toxin, which is responsible for the extensive loss of fluid and electrolytes from infected individuals. Cholera remains a worldwide problem. Although a number of live, attenuated or killed whole cell vaccine formulations have been tested, none have proven successful enough to result in their widespread use. This grant proposal focuses on new approaches to develop a cholera subunit vaccine formulation based on the current understanding of V. cholerae colonization, pathogenesis, and human immune responses to infection. The strategy will incorporate features of the highly successful Haemophilus influenzae type b and pertussis vaccines that utilize defined surface virulence determinants, colonization factors, and toxoids to achieve long-lasting protection. The present proposal will focus on formulations that include the toxin coregulated pilus (TCP) colonization factor, detoxified LPS, and the adjuvant cholerae toxin. The general goal for these studies is to define the most effective combination of TCP and LPS antigens that provide for protective humoral responses. We will characterize in detail the B cell epitopes for these antigens and determine which epitopes are minimally required for effective immunity. Studies will extend this information to human sera and demonstrate that the epitopes we have identified are operational in the field. Using a well- established mouse model, we will quickly be able to define the immunization regimen and immunogens that are likely candidates for extension into human trials. The proposed research formally brings together the expertise from two research groups at Dartmouth Medical School. Dr. William Wade is a molecular immunologist with training in structural and functional analyses of proteins as they relate to antigen presentation. His research focuses on methodologies to optimize the immunogenicity and delivery of antigens. Dr. Ronald Taylor's research focuses on the molecular basis of V. cholerae pathogenesis. He discovered TCP and his group has been instrumental in characterizing the tcpA gene and corresponding pilin protein as well as demonstrating that TCP is the major V. cholerae colonization factor and a protective antigen. Together, the expertise of these two research groups will provide a unique opportunity to develop and evaluate V: cholerae subunit vaccines using new approaches.

霍乱是一种由革兰氏阴性菌霍乱弧菌引起的急性腹泻疾病。在摄入受污染的食物或水后，细菌在小肠内定植并分泌霍乱毒素，这是造成受感染者大量流失液体和电解质的原因。霍乱仍然是一个世界性的问题。虽然已经测试了一些活的、减毒的或灭活的全细胞疫苗配方，但没有一种证明足够成功，可以广泛使用。这项拨款提案的重点是基于目前对霍乱弧菌定植、发病机制和人类对感染的免疫反应的理解，开发霍乱亚单位疫苗配方的新方法。该战略将结合非常成功的b型流感嗜血杆菌和百日咳疫苗的特点，利用确定的表面毒力决定因素、定植因子和类毒素来实现持久保护。目前的建议将集中于配方，包括毒素共调节菌毛（TCP）定植因子，解毒LPS，和佐剂霍乱毒素。这些研究的总体目标是确定提供保护性体液反应的TCP和LPS抗原的最有效组合。我们将详细描述这些抗原的B细胞表位，并确定哪些表位是有效免疫的最低要求。研究将把这一信息扩展到人类血清，并证明我们已经确定的表位在现场是可操作的。使用一个完善的小鼠模型，我们将很快能够确定免疫方案和免疫原，这些可能是扩展到人体试验的候选人。这项拟议中的研究正式汇集了达特茅斯医学院两个研究小组的专业知识。William Wade博士是一名分子免疫学家，在与抗原呈递相关的蛋白质结构和功能分析方面受过培训。他的研究重点是优化抗原免疫原性和递送的方法。罗纳德·泰勒博士的研究重点是霍乱弧菌发病机制的分子基础。他发现了TCP，他的团队在表征tcpA基因和相应的pilin蛋白以及证明TCP是霍乱弧菌的主要定植因子和保护性抗原方面发挥了重要作用。这两个研究小组的专业知识将共同为使用新方法开发和评估霍乱弧菌亚单位疫苗提供独特的机会。